Antibody-drug conjugates for metastatic urothelial carcinoma & 177Lu-PSMA-617 for Progressive mCRPC – Scott Tagawa

Scott Tagawa joins Alicia Morgans at the 26th Annual Prostate Cancer Foundation Scientific Retreat (PCF 2019) and discusses advances in bladder and prostate cancer. He highlights his recent work on antibody-drug conjugates (ADCs) in urothelial cancer and his presentation from ESMO on the initial results from TROPHY-U-01. Although immune checkpoint inhibitors now provide another option for…

Read the full article here

Source: UroToday

Categories: Urology

Tags: BladderCancer

Tweets with this article

UroToday.com

Antibody-drug conjugates for metastatic urothelial carcinoma & 177Lu-PSMA-617 for progressive mCRPC. @DrScottTagawa @WeillCornell and @CaPsurvivorship @NUFeinbergMed discuss advances in #BladderCancer & #ProstateCancer. #WatchNow on UroToday > https://t.co/7cXtwtWQBH @PCFnews https://t.co/MPoP5QbC55

Care for Patients with Nonmetastatic Castration-Resistant Prostate Cancer – Hanan Goldberg

Zach Klaassen and Hanan Goldberg discuss the evolving landscape of nonmetastatic castration-resistant prostate cancer (nmCRPC), highlighting the impact of PSMA PET scans on diminishing this…

UroToday.com October 15, 2024

AI-Based Assessment Tool for Predicting BCG Response in Bladder Cancer Patients – Yair Lotan

Ashish Kamat and Yair Lotan discuss an innovative AI-based assessment tool presented by Valar Labs, aimed at refining the management of BCG-unresponsive bladder cancer. Dr.…

UroToday.com October 15, 2024

Novel Hormonal Therapies for High-Risk Biochemical Recurrence: the EMBARK Trial – Stephen Freedland

Daniel George and Stephen Freedland delve into the EMBARK study, a trial on Enzalutamide for high-risk non-metastatic biochemical recurrence of prostate cancer. They explore the…

UroToday.com October 15, 2024

Operationalizing and Coordinating Lutetium-177 PSMA Treatment: Roles of a Multidisciplinary Prostate Cancer Team – Kristen Davis & Sarah Yenser Wood

Dan George discusses the collaborative effort in managing PLUVICTO® therapy for prostate cancer with team members Kristen Davis and Sarah Wood. Dr. Davis describes the…

UroToday.com October 15, 2024

Study Highlights Lubricity Differences Among Urological Catheters: Implications for Clinical Practice “Presentation” – Bruce Gao

At the World Congress of Endourology and Uro-Technology, Bruce Gao presents a study characterizing the lubricity of various urological catheters using a tribometer and a…

UroToday.com October 15, 2024

ARANOTE Study: Transforming Metastatic Hormone Sensitive Prostate Cancer Treatment – Fred Saad

Fred Saad discusses the ARANOTE phase 3 study results, evaluating darolutamide plus ADT in metastatic hormone-sensitive prostate cancer. The trial shows significant improvement in radiographic…

UroToday.com October 15, 2024

Communication for Optimal Care in Patients Selected for Triplet Therapy Between Urology and Community Oncology – Vahan Kassabian & Sreekanth Reddy

Zach Klaassen engages with Vahan Kassabian and Sreekanth to discuss the continuum of care for patients with metastatic hormone-sensitive prostate cancer, particularly in the context…

UroToday.com October 15, 2024

Related Articles